INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 285 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2023. The put-call ratio across all filers is 0.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $423 | -0.9% | 8,122 | +20.3% | 0.04% | -16.3% |
| Q2 2023 | $427 | +46.7% | 6,751 | +23.0% | 0.04% | +19.4% |
| Q4 2022 | $291 | -99.9% | 5,490 | -40.4% | 0.04% | -30.8% |
| Q1 2021 | $313,000 | +44.9% | 9,216 | -34.4% | 0.05% | -3.7% |
| Q1 2020 | $216,000 | -30.8% | 14,043 | -66.4% | 0.05% | +28.6% |
| Q3 2019 | $312,000 | +119.7% | 41,823 | +236.0% | 0.04% | +162.5% |
| Q4 2018 | $142,000 | -83.5% | 12,449 | -74.4% | 0.02% | -62.8% |
| Q2 2018 | $859,000 | -7.6% | 48,594 | +10.0% | 0.04% | -12.2% |
| Q1 2018 | $930,000 | -42.2% | 44,194 | -60.2% | 0.05% | -50.0% |
| Q4 2017 | $1,609,000 | +648.4% | 111,100 | +687.9% | 0.10% | +716.7% |
| Q3 2016 | $215,000 | -77.9% | 14,100 | -43.8% | 0.01% | -77.8% |
| Q2 2016 | $973,000 | +379.3% | 25,068 | +243.4% | 0.05% | +315.4% |
| Q1 2016 | $203,000 | – | 7,300 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |